NYSE:BSX

Boston Scientific - BSX Stock Forecast, Price & News

$48.50

+0.43 (+0.89%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: $47.87
▼
$48.87
50-Day Range: $43.79
▼
$48.50
52-Week Range: $34.98
▼
$48.87

Volume: 13.03 million shs
Average Volume: 7.57 million shs
Market Capitalization: $69.47 billion

P/E Ratio: 107.78
Dividend Yield: N/A
Price Target: $50.88

Institutional Ownership

Boston Scientific MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.94 Rating Score
Upside/Downside: 5.7% Upside
$51.27 Price Target
Short Interest: Healthy
1.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.98
Upright™ Environmental Score
News Sentiment: 0.29
Based on 38 Articles This Week
Insider Trading: Selling Shares
$9.56 M Sold Last Quarter
Proj. Earnings Growth: 13.68%
From $1.90 to $2.16 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

175th out of 1,028 stocks

Surgical & Medical Instruments Industry

17th out of 105 stocks

2.5

Analyst's Opinion

Consensus Rating
Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.27, Boston Scientific has a forecasted upside of 5.7% from its current price of $48.50.
Amount of Analyst Coverage
Boston Scientific has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.09% of the outstanding shares of Boston Scientific have been sold short.
Short Interest Ratio / Days to Cover
Boston Scientific has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Boston Scientific has recently increased by 10.63%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Boston Scientific does not currently pay a dividend.
Dividend Growth
Boston Scientific does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Boston Scientific has received a 67.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Cardiac resynchronization therapy (CRT) devices", and "Penile implants" products. See details.
Environmental Sustainability
The Environmental Impact score for Boston Scientific is -0.98.

2.9

News and Social Media Coverage

News Sentiment
Boston Scientific has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 38 news articles for Boston Scientific this week, compared to 9 articles on an average week.
Search Interest
35 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 338% compared to the previous 30 days.
MarketBeat Follows
12 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,561,634.00 in company stock.
Percentage Held by Insiders
Only 0.71% of the stock of Boston Scientific is held by insiders.
Percentage Held by Institutions
90.23% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Boston Scientific are expected to grow by 13.68% in the coming year, from $1.90 to $2.16 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Boston Scientific is 107.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.19.
Price to Earnings Ratio vs. Sector
The P/E ratio of Boston Scientific is 107.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.21.
Price to Earnings Growth Ratio
Boston Scientific has a PEG Ratio of 2.27. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Boston Scientific has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

January 30, 2023 | marketbeat.com

GE Healthcare Technology: Speculating On Dividends (BSX)

GE Healthcare released a solid report and gave steady guidance that includes ample room in the cash flow for a dividend, should the board choose to pay one.

January 9, 2023 | marketbeat.com

Is Medtronic Stock Ready to Revive? (BSX)

The world’s largest medical device maker Medtronic PLC (NYSE: MDT) stock has fallen since April 2022. However, shares may have bottomed out.

February 5, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

February 5, 2023 | americanbankingnews.com

JPMorgan Chase & Co. Boosts Boston Scientific (NYSE:BSX) Price Target to $55.00

February 3, 2023 | americanbankingnews.com

Research Analysts Issue Forecasts for Boston Scientific Co.'s Q1 2023 Earnings (NYSE:BSX)

February 3, 2023 | americanbankingnews.com

Jefferies Financial Group Comments on Boston Scientific Co.'s Q1 2023 Earnings (NYSE:BSX)

February 3, 2023 | americanbankingnews.com

Stifel Nicolaus Increases Boston Scientific (NYSE:BSX) Price Target to $52.00

February 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Humana (HUM)

February 5, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now!

February 2, 2023 | markets.businessinsider.com

8 Analysts Have This to Say About Boston Scientific

February 2, 2023 | finance.yahoo.com

Boston Scientific Corporation (NYSE:BSX) Q4 2022 Earnings Call Transcript

February 2, 2023 | markets.businessinsider.com

Raymond James Reaffirms Their Buy Rating on Boston Scientific (BSX)

February 1, 2023 | finance.yahoo.com

Boston Scientific (BSX) Lags Q4 Earnings Estimates

February 1, 2023 | msn.com

$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today

February 1, 2023 | markets.businessinsider.com

Boston Scientific Corp Q4 Profit Increases, but misses estimates

February 1, 2023 | msn.com

Boston Scientific slips as quarterly earnings miss guidance

February 1, 2023 | finance.yahoo.com

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

February 1, 2023 | finance.yahoo.com

Boston Scientific stock slides 5% premarket after profit miss

January 31, 2023 | marketwatch.com

Boston Scientific Corp. stock rises Tuesday, still underperforms market

January 31, 2023 | msn.com

A Preview Of Boston Scientific's Earnings

January 31, 2023 | finance.yahoo.com

Insiders at Boston Scientific Corporation (NYSE:BSX) sold US$3.5m worth of stock, possibly indicating weakness in the future

January 31, 2023 | americanbankingnews.com

Boston Scientific (BSX) to Release Quarterly Earnings on Wednesday

January 28, 2023 | americanbankingnews.com

Boston Scientific (NYSE:BSX) Upgraded by StockNews.com to Buy

January 26, 2023 | americanbankingnews.com

Boston Scientific Target of Unusually High Options Trading (NYSE:BSX)

January 25, 2023 | marketwatch.com

Boston Scientific Corp. stock rises Wednesday, outperforms market

January 25, 2023 | marketwatch.com

Boston Scientific Corp. stock rises Wednesday, outperforms market

January 24, 2023 | marketwatch.com

Boston Scientific Corp. stock outperforms competitors despite losses on the day

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Company Calendar

Last Earnings: 2/01/2023
Today: 2/05/2023
Next Earnings (Estimated): 4/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NYSE:BSX
CUSIP: 10113710
CIK: 885725
Web: www.bostonscientific.com
Phone: (508) 683-4000
Fax: 508-683-5675
Employees: 41,000
Year Founded: 1979

Price Target and Rating

Average Stock Price Forecast: $51.27
High Stock Price Forecast: $56.00
Low Stock Price Forecast: $43.00
Forecasted Upside/Downside: +4.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.94
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.45
Trailing P/E Ratio: 107.78
Forward P/E Ratio: 25.53
P/E Growth: 2.27
Net Income: $1.04 billion
Net Margins: 5.50%
Pretax Margin: 9.00%
Return on Equity: 14.36%
Return on Assets: 7.69%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 1.45
Quick Ratio: 0.95

Sales & Book Value

Annual Sales: $12.68 billion
Price / Sales: 5.48
Cash Flow: $2.39 per share
Price / Cash Flow: 20.29
Book Value: $11.66 per share
Price / Book: 4.16

Miscellaneous

Outstanding Shares: 1,432,311,000
Free Float: 1,422,142,000
Market Cap: $69.47 billion
Optionable: Optionable
Beta: 0.79

Social Links

Key Executives

Michael F. Mahoney
Chairman, President & Chief Executive Officer

Edward F. Mackey
Executive Vice President-Global Operations

Daniel J. Brennan
Chief Financial Officer & Executive Vice President

Jodi Eddy
Senior VP, Chief Information & Digital Officer

Ian T. Meredith
Global Chief Medical Officer & Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BSX Stock - Frequently Asked Questions

Should I buy or sell Boston Scientific stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BSX shares.
View BSX analyst ratings or view top-rated stocks.
What is Boston Scientific's stock price forecast for 2023?: 15 equities research analysts have issued 12-month price objectives for Boston Scientific's stock. Their BSX share price forecasts range from $43.00 to $56.00. On average, they expect the company's stock price to reach $51.27 in the next twelve months. This suggests a possible upside of 5.7% from the stock's current price.
View analysts price targets for BSX or view top-rated stocks among Wall Street analysts.
How have BSX shares performed in 2023?: Boston Scientific's stock was trading at $46.27 at the beginning of the year. Since then, BSX stock has increased by 4.8% and is now trading at $48.50.
View the best growth stocks for 2023 here.
Are investors shorting Boston Scientific?: Boston Scientific saw a increase in short interest in January. As of January 15th, there was short interest totaling 15,610,000 shares, an increase of 10.6% from the December 31st total of 14,110,000 shares. Based on an average trading volume of 6,830,000 shares, the short-interest ratio is currently 2.3 days.
View Boston Scientific's Short Interest.
When is Boston Scientific's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our BSX earnings forecast.
How were Boston Scientific's earnings last quarter?: Boston Scientific Co. (NYSE:BSX) posted its quarterly earnings results on Wednesday, February, 1st. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by $0.02. The medical equipment provider had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.24 billion. Boston Scientific had a net margin of 5.50% and a trailing twelve-month return on equity of 14.36%. Boston Scientific's revenue was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.45 earnings per share.
Read the conference call transcript.
What guidance has Boston Scientific issued on next quarter's earnings?: Boston Scientific updated its FY23 earnings guidance on Wednesday, February, 1st. The company provided earnings per share guidance of $1.86-1.93 for the period, compared to the consensus EPS estimate of $1.93. The company issued revenue guidance of ~$13.32-13.57 billion, compared to the consensus revenue estimate of $13.45 billion.
What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?: 947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Boston Scientific own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and Salesforce (CRM).
What is Boston Scientific's stock symbol?: Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
Who are Boston Scientific's major shareholders?: Boston Scientific's stock is owned by a number of retail and institutional investors. Top institutional investors include Newport Trust Co (0.49%), Allspring Global Investments Holdings LLC (0.31%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Fisher Asset Management LLC (0.26%), New York State Common Retirement Fund (0.20%) and Assenagon Asset Management S.A. (0.17%). Insiders that own company stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, David A Pierce, David S Wichmann, Edward F Mackey, Eric Francis Yves Thepaut, Ian T Meredith, Jeffrey B Mirviss, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Jonathan Monson, Joseph Michael Fitzgerald, Maulik Nanavaty, Meghan Scanlon, Michael F Mahoney, Michael F Mahoney, Nelda J Connors, Scott Olson, Wendy Carruthers and William F Bruss.
View institutional ownership trends.
How do I buy shares of Boston Scientific?: Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Boston Scientific's stock price today?: One share of BSX stock can currently be purchased for approximately $48.50.
How much money does Boston Scientific make?: Boston Scientific (NYSE:BSX) has a market capitalization of $69.47 billion and generates $12.68 billion in revenue each year. The medical equipment provider earns $1.04 billion in net income (profit) each year or $0.45 on an earnings per share basis.
How many employees does Boston Scientific have?: The company employs 41,000 workers across the globe.
Does Boston Scientific have any subsidiaries?: The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.
Read More
How can I contact Boston Scientific?: Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The official website for the company is www.bostonscientific.com. The medical equipment provider can be reached via phone at (508) 683-4000, via email at bsxinvestorrelations@bsci.com, or via fax at 508-683-5675.

This page (NYSE:BSX) was last updated on 2/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Boston Scientific - BSX Stock Forecast, Price & News

Boston Scientific MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Boston Scientific (NYSE:BSX) Stock

BSX Stock News Headlines

BSX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BSX Stock - Frequently Asked Questions

Overall MarketRank^™